Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization

Pharmacologically active compounds with known biological targets were evaluated for inhibition of SARS-CoV-2 infection in cell and tissue models to help identify potent classes of active small molecules and to better understand host-virus interactions. We evaluated 6,710 clinical and preclinical com...

Descripción completa

Detalles Bibliográficos
Autores principales: Patten, J.J., Keiser, Patrick T., Morselli-Gysi, Deisy, Menichetti, Giulia, Mori, Hiroyuki, Donahue, Callie J., Gan, Xiao, Valle, Italo do, Geoghegan-Barek, Kathleen, Anantpadma, Manu, Boytz, RuthMabel, Berrigan, Jacob L., Stubbs, Sarah H., Ayazika, Tess, O’Leary, Colin, Jalloh, Sallieu, Wagner, Florence, Ayehunie, Seyoum, Elledge, Stephen J., Anderson, Deborah, Loscalzo, Joseph, Zitnik, Marinka, Gummuluru, Suryaram, Namchuk, Mark N., Barabási, Albert-László, Davey, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374494/
https://www.ncbi.nlm.nih.gov/pubmed/35992305
http://dx.doi.org/10.1016/j.isci.2022.104925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374494/
https://www.ncbi.nlm.nih.gov/pubmed/35992305
http://dx.doi.org/10.1016/j.isci.2022.104925

Ejemplares similares